Emma Guttman-Yassky, MD, PhD
Emma Guttman-Yassky, MD, PhD, Waldman Professor and System Chair of Dermatology and Immunology, director of the Center for Excellence in Eczema and the Occupational Dermatitis Clinic and director of the Laboratory for Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai, discussed:
- Topical therapies she is using in clinical practice for atopic dermatitis (AD), including topical corticosteroids and “the newest agent on the block” Eucrisa (crisaborole, Pfizer);
- Treatments for severe disease, such as phototherapy, immunosuppressants and Dupixent (dupilumab, Sanofi and Regeneron Pharmaceuticals), which has “revolutionized the treatment of atopic dermatitis;”
- Drugs under development during this “very busy and exciting time for atopic dermatitis,” like oral JAK inhibitors and sphingosine-1-phosphate (S1P) receptor modulators;
- How the approval of Dupixent in children has “changed the way we treat AD;”
- Considerations when treating patients of color, such as being aware that redness isn’t always seen, the legions can be different and the importance of talking to patients about how AD affects them; and
- Greatest areas of unmet need, like the need for treatments to “tackle the entire atopic march very early” and something that will “switch around” the disease so patients can eventually stop taking treatment.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.